炎症组织启动:对炎症性风湿病的新见解与治疗机会
过去数十年优化治疗策略和新疗法的可用性使类风湿关节炎或系统性硬化症等曾具破坏性的慢性炎症疾病不再那么可怕,但许多患者即使接受最先进治疗仍无法诱导缓解,且抗炎治疗减量或停用后复发风险大幅增加,提示潜在病理过程在无明显炎症时仍活跃。组织具有记忆既往病原体、创伤和其他刺激并对其再次出现反应更强或更持久的能力,这种组织启动在防御微生物中起重要作用,但也驱动炎症病理。本文综述炎症组织启动的科学现状,聚焦关节炎和系统性硬化症中的组织驻留和占据组织的细胞,并反思针对这些疾病中适应不良组织反应的最有前景的治疗选择。
要点
- 许多患者即使接受最先进治疗仍无法诱导缓解,抗炎治疗减量或停用后复发风险大幅增加。
- 组织启动在防御微生物中起重要作用,但也驱动炎症病理。
- 长寿命组织驻留细胞与浸润免疫细胞及全身作用因子共同决定炎症组织启动。
核心结论
- 炎症组织启动在防御微生物中起重要作用,但也驱动炎症病理,长寿命组织驻留细胞与浸润免疫细胞及全身作用因子共同决定这一过程。
研究设计与样本
- 综述,聚焦关节炎和系统性硬化症中的组织驻留和占据组织的细胞,并反思针对适应不良组织反应的治疗选择。
主要发现
- 即使最先进治疗也无法使许多患者诱导缓解,抗炎治疗减量或停用后复发风险大幅增加,提示潜在病理过程在无明显炎症时仍活跃。
- 组织能记忆既往病原体、创伤和其他刺激,并对再次出现反应更强或更持久。
- 长寿命组织驻留细胞如成纤维细胞、巨噬细胞、长寿命浆细胞和组织驻留记忆T细胞与浸润的淋巴和髓系免疫细胞及细胞因子、细胞外囊泡和抗体等全身作用因子相互作用决定炎症组织启动。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Due to optimised treatment strategies and the availability of new therapies during the last decades, formerly devastating chronic inflammatory diseases such as rheumatoid arthritis or systemic sclerosis (SSc) have become less menacing. However, in many patients, even state-of-the-art treatment cannot induce remission. Moreover, the risk for flares strongly increases once anti-inflammatory therapy is tapered or withdrawn, suggesting that underlying pathological processes remain active even in the absence of overt inflammation. It has become evident that tissues have the ability to remember past encounters with pathogens, wounds and other irritants, and to react more strongly and/or persistently to the next occurrence. This priming of the tissue bears a paramount role in defence from microbes, but on the other hand drives inflammatory pathologies (the Dr Jekyll and Mr Hyde aspect of tissue adaptation). Emerging evidence suggests that long-lived tissue-resident cells, such as fibroblasts, macrophages, long-lived plasma cells and tissue-resident memory T cells, determine inflammatory tissue priming in an interplay with infiltrating immune cells of lymphoid and myeloid origin, and with systemically acting factors such as cytokines, extracellular vesicles and antibodies. Here, we review the current state of science on inflammatory tissue priming, focusing on tissue-resident and tissue-occupying cells in arthritis and SSc, and reflect on the most promising treatment options targeting the maladapted tissue response during these diseases.
引用
- Hoffmann MH, Kirchner H, Krönke G, et al. Inflammatory tissue priming: novel insights and therapeutic opportunities for inflammatory rheumatic diseases. Ann Rheum Dis. 2024. PMID: 38702177. doi:10.1136/ard-2023-224092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。